HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644.

AbstractOBJECTIVES:
The purpose of this study was to test the hypothesis that the longer duration of ventricular action potentials in hypertrophied hearts predisposes to the development of early after-depolarizations and triggered ventricular tachyarrhythmias.
BACKGROUND:
For unknown reasons, the incidence of sudden death is greater in patients with myocardial hypertrophy.
METHODS:
We measured left ventricular monophasic action potentials in normal dogs and dogs with left ventricular hypertrophy before and after administration of the calcium agonist BAY K 8644 and the potassium channel blocker cesium.
RESULTS:
We demonstrated longer action potential durations in dogs with than in those without left ventricular hypertrophy. Also, BAY K 8644 produced phase 2 early afterdepolarizations and ventricular tachyarrhythmias more frequently in the dogs with than in those without left ventricular hypertrophy. Phenylephrine, an alpha agonist, further increased the action potential duration in hypertrophied hearts and the propensity to develop early afterdepolarizations and ventricular tachyarrhythmia after administration of BAY K 8644. Control and hypertrophied hearts developed early afterdepolarizations and ventricular tachyarrhythmia equally when exposed to cesium.
CONCLUSIONS:
Although in vitro studies have shown that fibers of hypertrophied ventricular myocardium can develop triggered activity as a result of both early and late afterdepolarizations, the present study is the first to show in vivo that the hypertrophied ventricular myocardium compared with the normal ventricle is predisposed to develop phase 2 early afterdepolarizations that appear to trigger ventricular tachyarrhythmia. It is possible that such a mechanism contributes to the development of ventricular tachyarrhythmia and sudden cardiac death in patients with left ventricular hypertrophy. If this is shown to be true, specific pharmacologic interventions can be suggested.
AuthorsJ Ben-David, D P Zipes, G M Ayers, H P Pride
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 20 Issue 7 Pg. 1576-84 (Dec 1992) ISSN: 0735-1097 [Print] United States
PMID1280660 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Cesium
  • Phenylephrine
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
Topics
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester (administration & dosage, adverse effects)
  • Action Potentials (drug effects)
  • Animals
  • Causality
  • Cesium (adverse effects)
  • Death, Sudden, Cardiac (epidemiology, etiology)
  • Disease Models, Animal
  • Dogs
  • Evaluation Studies as Topic
  • Hemodynamics (drug effects)
  • Hypertrophy, Left Ventricular (complications, drug therapy, pathology)
  • Incidence
  • Organ Size (drug effects)
  • Phenylephrine (adverse effects)
  • Prevalence
  • Tachycardia, Ventricular (chemically induced, diagnosis, epidemiology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: